Summary:
A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults With Major Depressive Disorder
Qualified Participants Must:
• Be suffers from recurrent major depressive disorder (MDD)
•
Have had at least 2 other major depressive episodes (MDEs) before the current episode
•
Is a man or woman aged 18 to 75 years
•
Negative drug screen
Qualified Participants May Receive:
$75.00 per completed visit, Free medication, Free evaluations